Drug
Stalevo
Stalevo: highest development phase Post-Market, developed by Orion Corporation. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Orion Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Stalevo (levodopa/carbidopa/entacapone) NCT00125567 | Post-Market | Idiopathic Parkinson's Disease |
| Stalevo NCT02764125 | Phase 2 | Parkinson's Disease |
| Stalevo (levodopa/ carbidopa/ entacapone) NCT01070628 | Phase 1 | Parkinson's Disease |
Latest
No recent events.
Follow Stalevo on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.